What is the number of patients that need to be treated (NNT) with omalizumab to prevent one hospitalization for asthma exacerbation?
The number needed to treat (benefit) (NNTB) is 33.
In a recent meta-analysis, during the stable-steroid phase, the asthma exacerbation rate was lower in the omalizumab group (RR, 0.57, NNTB, 10). There were significantly fewer hospitalizations from asthma exacerbation in the omalizumab group (RR, 0.44; NNTB, 33).
Patients treated with omalizumab were more likely to withdraw from corticosteroid treatment completely vs the placebo group (RR, 1.80; NNTB, 5). A higher proportion in the omalizumab group was able to reduce corticosteroid dosage by 50% or more (RR, 1.34; NNTB, 5).
Severe asthma - differential diagnosis and management (click to enlarge the image). Related: Common Asthma-related Comorbidities. Medscape, 2011, (figure) http://j.mp/omHVc6
Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Chest. 2011 Jan;139(1):28-35.
Humanized Monoclonal Antibody May Be Effective, Safe in Asthma Patients. Medscape, 2011.
"Super-omalizumab" new monoclonal XmAb7195 has 5-fold higher affinity for IgE, 400-fold higher affinity for FcγRIIb. JACI, 2012.
Omalizumab in children with severe persistent asthma uncontrolled on standard therapy - AAAAI Ask the Expert answers: http://goo.gl/rpxTX
Image source: Wikipedia, public domain.